Tuesday, October 15, 2024
Today's Paper

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

Lead indication for ZyVersa's Inflammasome ASC Inhibitor IC 100 is obesity with metabolic complications.

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

See our subscription options.

Already have an account? Log in here